747 related articles for article (PubMed ID: 15246845)
1. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterases in cardiac ganglia and modulation of canine intrinsic cardiac neuronal activity.
Darvesh S; MacDonald SE; Losier AM; Martin E; Hopkins DA; Armour JA
J Auton Nerv Syst; 1998 Jul; 71(2-3):75-84. PubMed ID: 9760044
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
4. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
5. Chimeric human cholinesterase. Identification of interaction sites responsible for recognition of acetyl- or butyrylcholinesterase-specific ligands.
Loewenstein Y; Gnatt A; Neville LF; Soreq H
J Mol Biol; 1993 Nov; 234(2):289-96. PubMed ID: 8230213
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease.
Darvesh S; Walsh R; Kumar R; Caines A; Roberts S; Magee D; Rockwood K; Martin E
Alzheimer Dis Assoc Disord; 2003; 17(2):117-26. PubMed ID: 12794390
[TBL] [Abstract][Full Text] [Related]
7. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis F
Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
[TBL] [Abstract][Full Text] [Related]
8. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.
Poirier J
Int J Clin Pract Suppl; 2002 Jun; (127):6-19. PubMed ID: 12139368
[TBL] [Abstract][Full Text] [Related]
9. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
Nordberg A; Darreh-Shori T; Peskind E; Soininen H; Mousavi M; Eagle G; Lane R
Curr Alzheimer Res; 2009 Feb; 6(1):4-14. PubMed ID: 19199870
[TBL] [Abstract][Full Text] [Related]
10. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus.
Darvesh S; Hopkins DA
J Comp Neurol; 2003 Aug; 463(1):25-43. PubMed ID: 12811800
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of cholinesterase in two snails Pila globosa and Lymnaea acuminata.
Singh DK; Singh O; Agarwal RA
J Physiol (Paris); 1982; 78(5):467-72. PubMed ID: 7184992
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
[TBL] [Abstract][Full Text] [Related]
13. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
14. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman.
Gordon RK; Haigh JR; Garcia GE; Feaster SR; Riel MA; Lenz DE; Aisen PS; Doctor BP
Chem Biol Interact; 2005 Dec; 157-158():239-46. PubMed ID: 16256090
[TBL] [Abstract][Full Text] [Related]
16. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
17. Switching cholinesterase inhibitors in patients with Alzheimer's disease.
Emre M
Int J Clin Pract Suppl; 2002 Jun; (127):64-72. PubMed ID: 12139369
[TBL] [Abstract][Full Text] [Related]
18. Interaction of tetrahydroaminoacridine with acetylcholinesterase and butyrylcholinesterase.
Berman HA; Leonard K
Mol Pharmacol; 1992 Feb; 41(2):412-8. PubMed ID: 1538717
[TBL] [Abstract][Full Text] [Related]
19. Cholinesterases: new roles in brain function and in Alzheimer's disease.
Giacobini E
Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
Giacobini E
Drugs Aging; 2001; 18(12):891-8. PubMed ID: 11888344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
